IceCure Reports 83% U.S. Sales Growth and Expanded U.S. Commercial Reach to 21 States for Nine Months Ended September 30, 2026
IceCure Medical reported nine-month 2026 revenues of $2.64 million, a 26% increase year-over-year, with U.S. sales increasing 83% year-over-year during the first nine months of 2026 compared to the same period in 2025. The company expanded its U.S. commercial presence from 11 states in Q3 2025 to 21 states in Q3 2026. Net loss widened to $12.99 million from $10.81 million year-over-year, while cash and cash equivalents totaled approximately $8.2 million as of September 30, 2026.
Key takeaways
Nine-month 2026 revenue increased approximately 26% to $2.64 million from $2.1 million in the prior-year period.
U.S. sales doubled year-over-year during the first nine months of 2026, representing 83% year-over-year growth.
U.S. commercial reach expanded from 11 states in Q3 2025 to 21 states in Q3 2026.
Gross profit increased approximately 22% to $762,000 from $626,000 year-over-year.
Operating loss widened to $12.99 million from $10.88 million year-over-year, primarily reflecting increased R&D expenses related to the ChoICE Study.
R&D expenses increased to $6.56 million from $5.14 million year-over-year.
Sales and marketing expenses increased to $3.67 million from $3.06 million year-over-year.
Key metrics
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open Investor relationsFollow ICCM in real time
Get material earnings, filing, IR, and earnings-call alerts by email.